AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains ...

The clinical-stage biotechnology company announced an 85% remission rate in evaluable frontline AML patients treated with mipletamig in combination with standard-of-care venetoclax and azacitidine.

Mipletamig, a CD3 x CD123 bispecific antibody, is being investigated as frontline therapy in combination with venetoclax and azacitidine, a current standard of care for AML. These latest results ...

--(BUSINESS WIRE)--Amphivena Therapeutics Inc., a privately held biotechnology company developing a novel CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and ...

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell ... engages CD3 on T cells ...

AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among ...